



ASX Release

28 May 2026

Acrux licenses Lenzetto® for the Australian market for AUD 5.4 million

The pending Australian market entry of Estradiol spray Lenzetto® will help address a critical shortage of Menopause Hormone Therapy products in the country

Highlights:

- Acrux executes an amendment to its licensing agreement for transdermal Estradiol spray Lenzetto®.
- Under this amended agreement, Acrux will receive upfront, regulatory, and commercial milestone payments from Gedeon Richter Plc for Lenzetto® in the Australian market. The terms are commercial-in-confidence.
- Total milestone payments for the agreement could total up to AUD 5.4 million to be received within two years from the product's launch.
- The agreement means Lenzetto® will now help address a critical shortage of Menopause Hormone Therapy (MHT) products in the Australian market.

Melbourne, Australia – 28 May 2026: Specialty pharmaceuticals group **Acrux Limited (ASX:ACR)** (the **Company** or **Acrux**) is pleased to announce the execution of an amendment to its licensing agreement for Lenzetto® with long-time partner Gedeon Richter Plc (**Richter**).

The amended agreement will see Acrux receive milestone payments from Richter for Lenzetto® in the Australian market. These milestone payments could total up to AUD 5.4 million, to be received within two years from launch and including an upfront payment and regulatory and commercial milestones.

Acrux-developed MHT product Lenzetto® already has a global footprint

Lenzetto® was developed by Acrux and is already licensed to and marketed by Gedeon Richter in more than 40 countries worldwide with sales of EUR 50 million in 2025. It is a transdermal Estradiol spray which is a hormone replacement therapy (HRT) treatment of symptoms associated with oestrogen deficiency occurring in women after menopause such as hot flashes.



Figure 1: Lenzetto, a novel Estradiol spray for women

Estradiol is delivered by the Company's unique Patchless Patch™ delivery technology. This technology was invented at Monash University and has helped change the lives of women all over the world.

John Warmbrunn, Acrux CEO and Managing Director, said:

“The expansion of our existing licensing agreement with long-term partner Gedeon Richter paves the way for Acrux’s transdermal Estradiol spray Lenzetto® to deliver clear benefits to both Australian women and Acrux’s financials.

Getting this locally developed Estradiol spray into the hands of Australian women has been a key priority of ours for some time. The amended agreement with Richter means Australian women suffering oestrogen deficiency after menopause will soon have access to this hormone replacement therapy treatment,

From a financial performance angle, the extended agreement is set to deliver Acrux additional milestone payments of up to AUD5.4 million over the coming years. These payments place Acrux in a strong position as the Company continues to work towards bringing its innovative Female Testosterone product to market.”

Felicia Colagrande, Acrux Product Development and Technical Affairs Director, said:

“I am so delighted that Acrux has been able to get our Lenzetto®, Patchless Patch™ into Australia. It means Australian women will have a precise, consistent, discrete and easy to use option for their MHT.”

About Gedeon Richter Plc

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8 billion and sales of EUR 2.3 billion in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation.

Learn more at www.gedeonrichter.com

This announcement has been authorised for release to the ASX by the Board of Acrux.

For more information, please contact:

John Warmbrunn

CEO & Managing Director

E: john.warmbrunn@acrux.com.au

P: + 61 3 8379 0100

Julia Maguire

Media Relations

The Capital Network

E: julia@thecapitalnetwork.com.au

P: +61 2 7257 7338

About Acrux

Acrux Limited (ASX:ACR) is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

For further information on Acrux, visit: www.acrux.com.au